Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Swiss Red Cross

Latest From Swiss Red Cross

Cerenis: Aspiring to Esperion?

When Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics in March 2005, he was doubtless inspired partly by Esperion's $1.25 billion sale to Pfizer in December 2003. So were a handful of top-notch VCs including Sofinnova Partners and HealthCap (a previous investor in Esperion), who poured in €25 million ($30.5 million) in August 2005.

BioPharmaceutical Business Strategies

Going Back to School

Often started by the academic inventors or their laboratory acolytes, biotechs offer equity participations (to universities and researchers) as well as focused attention to their inventions. As large companies have steadily invested in and improved their own discovery operations, in particular going further into the basic research which is the stuff of academic labs, they find themselves positioned to exploit university research in a more focused way-and thus are more willing than ever to do universi

See All

Company Information